arrow
L

Lukas Makris

stathmi, inc
H指数:19
被引数:3,526

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term treatment of homozygous familial hypercholesterolemia with lomitapide: 11 years of safety and effectiveness findings from the Lomitapide Observational Worldwide Evaluation Registry (LOWER)

纯合子家族性高胆固醇血症的长期洛美他派治疗:来自洛美他派全球观察评估登记研究(LOWER)11年的安全性与有效性结果

2026-07-300
OAAI
MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors

MDX-2001-101研究方案:一项评估MDX2001单药治疗在晚期实体瘤患者中的I/IIa期、多中心、首次人体、开放标签临床试验

2026-01-010
OA
A phase I/IIa first-in-human clinical trial evaluating MDX2001, a multi-specific antibody in patients with advanced solid tumor malignancies

一项评估MDX2001(一种多特异性抗体)在晚期实体瘤恶性肿瘤患者中的首次人体I/IIa期临床试验。

2024-09-010
PRE
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)
2022-01-088
OAAI
Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials
2020-01-0146
OAAI
The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
2018-02-0164
OAAI